Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events
| dc.contributor.author | Bongomin, Felix | |
| dc.contributor.author | Maguire, Niamh | |
| dc.contributor.author | Moore, Caroline B. | |
| dc.contributor.author | Felton, Timothy | |
| dc.contributor.author | Rautemaa-Richardson, Riina | |
| dc.date.accessioned | 2023-11-30T10:55:20Z | |
| dc.date.available | 2023-11-30T10:55:20Z | |
| dc.date.issued | 2018-12-13 | |
| dc.description.abstract | Background: Long-term oral triazole antifungal therapy is the cornerstone of man agement for patients with chronic pulmonary aspergillosis (CPA). Itraconazole is the first-line choice of treatment. Voriconazole, posaconazole or isavuconazole can be used as alternative treatments in case of resistance or intolerance. All of these can cause significant adverse drug reactions. Objectives: To evaluate how CPA patients tolerate voriconazole and isavuconazole after prior triazole therapy. Methods: We performed a retrospective observational study at the UK National Aspergillosis Centre. Medical records for all consecutive CPA patients started on isa vuconazole and voriconazole during an observation period of 12 and 6 months re spectively were analysed. Results: During this study period, 20 patients were started on isavuconazole and 21 patients on voriconazole. Adverse events were seen in 18 of 21 (86%) the patients in the voriconazole group and 12 of 20 (60%) in the isavuconazole group (P = 0.02). For those who developed adverse events to these agents, the rates of discontinuation of therapy were comparable (ie 10/18 [56%], voriconazole vs 8/12 [67%], isavucona zole; P = 0.54). Five (25%) patients in the isavuconazole group who were intolerant to other triazoles tolerated the standard dose of isavuconazole. Conclusions: Compared with isavuconazole, adverse events were significantly higher in CPA patients commenced on voriconazole. Isavuconazole may be an option for those patients who are intolerant to other triazoles. | en_US |
| dc.identifier.citation | Bongomin, F., Maguire, N., Moore, C. B., Felton, T., & Rautemaa‐Richardson, R. (2019). Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events. Mycoses, 62(3), 217-222. | en_US |
| dc.identifier.other | DOI: 10.1111/myc.12885 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14270/410 | |
| dc.language.iso | en | en_US |
| dc.publisher | Mycoses | en_US |
| dc.relation.ispartofseries | ;3 | |
| dc.subject | adverse events, | en_US |
| dc.subject | chronic pulmonary aspergillosis, | en_US |
| dc.subject | isavuconazole, | en_US |
| dc.subject | voriconazole | en_US |
| dc.title | Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events | en_US |
| dc.type | Article | en_US |